BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
March 2, 2005
View Archived Issues
Vernalis Getting £30M With Plans To Build Sales Force
Read More
Novel Monoclonal Technology Might Bring Raft Of Therapies
Read More
With Partner Re-Evaluating, Phytopharm Pulls Funding
Read More
Stirling Medical Solutions Gets Funding From ITI, IMI
Read More
Opsona Raises EUR6.25M For Anti-Inflammatory Products
Read More
Other News To Note
Read More
Biogen Idec, Elan Plummet On Withdrawal Of Tysabri
Two serious adverse events - one ending in death - was enough for Biogen Idec Inc. and Elan Corp. plc to suspend marketing of their multiple sclerosis drug, Tysabri, just three months after FDA approval. (BioWorld International)
Read More